IL-12 is a key melanoma response marker: immunotherapy.(Clinical Rounds )(Interleukin-12)(Brief Article)
Publication: Skin & Allergy News
Publication Date: 01-DEC-03
Author: Bates, Betsy
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
CHICAGO -- Enhanced interleukin-12 gene expression from peripheral blood monocytes may predict which stage IV melanoma patients are responding to active specific immunotherapy, while rising interleukin-10 gene expression appears to portend a poor prognosis.
The findings from a small study by Dr. Alan S. Kadison and associates at the...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
